Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 )
EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 )
Associated Disease
lung adenocarcinoma
Source Database
CIViC Evidence
Description
Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1395
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/562
Rating
2
Evidence Type
Predictive
Disease
Lung Adenocarcinoma
Evidence Direction
Supports
Drug
Gefitinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
20522446
Drugs
Drug NameSensitivitySupported
GefitinibSensitivitytrue